West Pharmaceutical Raises Dividend 18.2% to $0.26

West Pharmaceutical Services increased its quarterly dividend 18.2% to $0.26 a share from $0.22. The stock’s next ex-dividend date is November 10, 2026, and the payment date is November 18, 2026.

Why the dividend changed

West’s dividend notice announced the higher payment without linking it to a one-time transaction or providing a detailed explanation for the increase. Nothing in the declaration identifies a stock split, merger or spinoff as the reason for the change. The available operating evidence instead points to stronger business performance and ample earnings coverage as the context for the board’s decision. West’s dividend declaration

The company reported second-quarter net sales of $872.3 million, an increase of 13.8%, while organic sales grew 12.7%. Adjusted diluted earnings per share increased 28.8%. West attributed the performance to High Value Product Components, including continued demand from biologic medicines, GLP-1 elastomers and upgrades related to European Annex 1 manufacturing requirements. The company raised its full-year net-sales guidance to $3.345 billion to $3.380 billion and its adjusted diluted earnings-per-share guidance to $8.85 to $9.05. West’s second-quarter results

Cash generation and capital allocation provide additional context. West reported $213.9 million of operating cash flow and $128.0 million of free cash flow for the first half. It also repurchased 1.8 million shares for $454.3 million under a program announced in February, showing that the dividend increase forms one part of a broader return-of-capital program. The company maintained capital-spending guidance of $250 million to $275 million, preserving substantial investment in capacity, automation and product development. West’s second-quarter results

West also completed the sale of the manufacturing and supply rights for its SmartDose 3.5mL system on July 1. The company retained other SmartDose versions, including its 10mL system, making the transaction a portfolio adjustment rather than a separation of the broader drug-delivery business. West did not identify the sale as the direct cause of the dividend increase. West’s SmartDose announcement

Dividend track record

The increase extends West’s record to 33 consecutive years of dividend growth. The five-year pace is 5.6% annual growth, making the new 18.2% increase a larger step than the company’s recent annual progression.

Full-year distributions rose from $0.65 in 2020 to $0.69 in 2021, $0.73 in 2022, $0.77 in 2023, $0.81 in 2024 and $0.85 in 2025. The corresponding annual increases moderated from 6.2% in 2021 to 5.8%, 5.5%, 5.2% and 4.9% in the following years. Recent quarterly payments followed the same measured pattern: four recorded payments of $0.21 were followed by four at $0.22 before the move to $0.26.

At the new rate, the indicated annual dividend is $1.04 a share. That equates to $104.00 of annual income for every 100 shares, assuming the rate remains unchanged.

Is the dividend covered?

The dividend consumes 11% of earnings. That low payout ratio means most earnings remain available for operations, capital investment, acquisitions, debt obligations and share repurchases after the dividend is paid.

SmarterDividends rates the dividend A with a safety score of 98, placing it in the very safe range of score 80-100. The grade reflects the combination of the low earnings payout and the established growth record. It does not mean the payment is guaranteed, but it indicates that the current dividend represents a small claim on reported earnings.

Yield and valuation

At a share price of $394.73, West’s forward yield is 0.26%. That is well below the Healthcare sector median forward yield of 1.66%. The dividend therefore provides less current income than the sector median even after the increase.

The shares have recorded a 41.4% gain over one year. SmarterDividends’ fair-value estimate is $156.02, producing an overvalued verdict and 60% downside to fair value. The contrast between the market price and fair-value estimate is material because the low yield reflects both the dividend rate and the price investors pay for each share.

What to watch

The immediate dividend milestones are the November 10, 2026 ex-dividend date and the November 18, 2026 payment date. Investors must own shares before the ex-dividend date to qualify under standard market settlement rules.

Operationally, the next earnings update will show whether demand for biologics, GLP-1 elastomers and Annex 1 upgrades continued to support the raised full-year guidance. Cash generation, the pace of capital spending and additional repurchases will help show how management is balancing reinvestment with shareholder returns. West’s second-quarter results

The update will also be an early test for Michel Lagarde, who became president and chief executive officer on August 31, succeeding Eric Green. Execution under the new leadership team and progress after the SmartDose 3.5mL sale are the principal company-specific developments to monitor alongside the higher dividend. West’s CEO-transition announcement